title: HIV vaccine development: strategies for preclinical and clinical investigation.
abstract: This article discusses HIV vaccine discovery and candidate vaccine testing in the context of current realities of funding and clinical trial practice. Lacking perfect animal models for testing candidate HIV vaccines, clinical investigators have proposed a strategy of iterative exploratory clinical trials in the model of cancer chemotherapy development. Problems with the appropriateness of this model to HIV vaccine development are discussed. Also, the future feasibility of this strategy in the context of increasing clinical trial costs and emerging new, efficacious prevention modalities is questioned. Strategies for making better use of animal models are presented as an alternative to iterative exploratory clinical efficacy testing. Some ways in which better data from preclinical studies can refine clinical product development are described. Finally, development of an HIV vaccine under the FDA's "Animal Rule" pathway to licensure when human efficacy studies are not feasible is discussed as a fall-back approach. Not making a preventive vaccine against HIV infection is simply not an option because eradication of AIDS will require a preventive vaccine.
authors: Vaccine Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases , Bethesda, Maryland.
authors: Stuart Z
authors: SZ
authors: Shapiro
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology* / Q000302:isolation & purification*; D000818:Animals; D055808:Drug Discovery / Q000379:methods*; D004341:Drug Evaluation / Q000379:methods*; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D015658:HIV Infections / Q000517:prevention & control*; D006801:Humans; D023421:Models, Animal
chemical_list: D016915:AIDS Vaccines
references: J Virol. 1999 May;73(5):4009-18
references: 10196297
references: AIDS Res Hum Retroviruses. 2011 Dec;27(12):1259-69
references: 21732792
references: Nat Med. 2012 Nov;18(11):1673-81
references: 22961108
references: Pediatr Res. 1973 Mar;7(3):103-10
references: 4120458
references: Nat Med. 2004 Aug;10(8):806-10
references: 15286782
references: J Exp Med. 2009 May 11;206(5):1117-34
references: 19414559
references: Vaccine. 1993;11 Suppl 1:S9-14
references: 8383390
references: Nature. 2007 Sep 6;449(7158):101-4
references: 17805298
references: Am J Hyg. 1956 May;63(3):217-27
references: 13313523
references: AIDS Res Hum Retroviruses. 2012 Jun;28(6):532-9
references: 22206265
references: Sci Transl Med. 2011 Apr 20;3(79):79ps13
references: 21508308
references: PLoS Med. 2008 Aug 12;5(8):e173
references: 18700814
references: J Virol. 2010 Jul;84(14):7083-95
references: 20463069
references: Nature. 2012 Jan 04;482(7383):89-93
references: 22217938
references: Am J Hyg. 1956 Sep;64(2):243-58
references: 13362234
references: J Immunol. 1946 Dec;54(4):325-47
references: 20278364
references: J Virol. 1997 Oct;71(10):7198-206
references: 9311792
references: J Hyg (Lond). 1978 Dec;81(3):383-8
references: 366017
references: Vaccine. 2012 Feb 21;30(9):1737-45
references: 22178526
references: Proc Natl Acad Sci U S A. 2008 May 27;105(21):7552-7
references: 18490657
references: AIDS Res Hum Retroviruses. 2012 Jul;28(7):641-8
references: 21861777
references: J Exp Med. 1945 Jan 1;81(1):93-117
references: 19871448